Skip to main content
Premium Trial:

Request an Annual Quote

Paired Ends: Don Henricksen, Robert Nussbaum, Hesaam Esfandyarpour, Ron Davis, George Church, and More

Premium

Cofactor Genomics has hired Don Henricksen as its North American sales director. Henricksen joins Cofactor after 16 years at PerkinElmer, most recently as a regional manager in the company's bio-discovery division. Previously he was a scientist at MDS Pharma and also at Roche. He holds a BS in biology from La Sierra University and Loma Linda University, in California.


Complete Genomics has formed a genomic medicine advisory board. Robert Nussbaum will serve as chairman. He is currently chief of the division of genetics in the department of medicine and director of the Cancer Risk and Cardiovascular Genetics Programs at the University of California, San Francisco.

Other members include Jonathan Berg, assistant professor in the department of genetics at the University of North Carolina; Charis Eng, chair and director of the Genomic Medicine Institute at the Cleveland Clinic; Brynn Levy, associate professor of clinical pathology and cell biology and co-director of the division of personalized genomic medicine at the College of Physicians and Surgeons of Columbia University and director of the clinical cytogenetics laboratory at the New York Presbyterian Hospital at Columbia University Medical Center; Elaine Lyon, associate professor of pathology at the University of Utah School of Medicine and medical director of the genetics division, and co-medical director of pharmacogenomics at Arup Laboratories; Federico Monzon, associate professor of pathology and immunology and director of molecular pathology at the Cancer Genetics Laboratory at Baylor College of Medicine; DesiRae Muirhead, assistant professor of pathology at Sanford School of Medicine at the University of South Dakota; Sterling Puck, former vice president for medical affairs at Genzyme Genetics; and Heidi Rehm, director of the Laboratory for Molecular Medicine at Partners HealthCare Center for Personalized Genetic Medicine and assistant professor of pathology at Harvard Medical School.


Sequencing startup GenapSys has disclosed members of its management team, scientific advisory board, and business advisory board (see related story, this issue).

Co-founder Hesaam Esfandyarpour serves as acting CEO and chief technology officer. He holds a BSc from Sharif University of Technology in Iran and an MS in electrical engineering, an MS in management science and engineering, and a PhD in electrical engineering from Stanford University.

GenapSys' scientific advisory board includes Ron Davis, professor of biochemistry and genetics and director of the Stanford Genome Technology Center; George Church, professor of genetics at Harvard Medical School; Mike Snyder, chair of genetics and director of the Center for Genomics and Personalized Medicine at Stanford; Steve Quake, professor of bioengineering at Stanford; Juan Santiago, professor of mechanical engineering at Stanford; Luke Lee, professor of bioengineering at the University of California, Berkeley; and Bruce Wooley, professor of engineering at Stanford.

The business advisory board includes André Marion, a co-founder of Applied Biosystems who was chairman, CEO, and president of the company at the time of its merger with Perkin-Elmer in 1993 and retired in 1995; Herb Heyneker, an early Genentech employee who has served as senior vice president of research and development at Crucell, CTO of Eos Biotechnology, and other roles in life science and biotech firms; and Dennis Harris, a co-founder of IntegenX who formerly served as chief scientific officer at Millipore and held management positions at Serologicals, Vitra Bioscience, Aclara Biosciences, and Amersham Pharmacia Biotech, now part of GE Healthcare.

The Scan

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.

Sequencing Study Leads to Vaccine Target in Bacteria Behind Neonatal Meningitis

Researchers eBioMedicine track down potential vaccine targets with transposon sequencing on mutant bacteria causing neonatal meningitis in mouse models of the disease.

Multiple Myeloma Progression Influenced by Immune Microenvironment Expression

Researchers in NPJ Genomic Medicine compare RNA sequencing profiles of 102,207 individual cells in bone marrow samples from 18 individuals with rapid or non-progressing multiple myeloma.

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.